Disappointing COVID-19, Flu and RSV Vaccination Rates Reported

As the influenza and Respiratory syncytial virus (RSV) seasons diminish in the U.S., world leaders express their disappointment with respiratory disease vaccination rates.

"Too many people are in need of serious medical care for flu, for COVID, when we can prevent it," said Maria Van Kerkhove, the World Health Organization's interim director of epidemic and pandemic preparedness, as reported by Reuters on January 12, 204.

Kerhove cited "incredibly low" vaccination rates against flu and COVID-19 in many countries this season.

According to the U.S. Centers for Disease Control and Prevention's (CDC) latest data, the percentage of the population reporting receipt of COVID-19, influenza, and RSV vaccines remains low for adults.

• The updated 2023-24 COVID-19 vaccine is 21.4% for adults 18+, including 41.5% for adults 65+.
• Influenza vaccination is 46.8% for adults 18+, including 74.1% among adults 65+.
• RSV vaccinations for adults over 60 years of age is 20.1%.

As of January 12, 2024, the CDC recommends that all six months and older stay current on COVID-19 and receive a seasonal flu vaccine.

Furthermore, if you are 60 years and older, talk to a healthcare provider to see if RSV vaccination is proper for you this season.

These reportatory vaccines are generally available at U.S.-based pharmacies. 

For new mothers, the extended half-life monoclonal antibody Beyfortus™ offers passive immunization for infants and young children to prevent lower respiratory tract infections caused by RSV. 

Beyfortus was recently approved for use in China, and the manufacturers have committed to deliver significant quantities to the U.S. in 2024.